LONDON, Oct. 26 /PRNewswire-FirstCall/ -- IMPAC Medical Systems, , a leading provider of information technology solutions for oncology care, announced today that the London Oncology Clinic LLP has selected IMPAC’s specialised chemotherapy electronic charting, practice management, and statistical analysis solutions for its newly refurbished clinic at 95 Harley Street. IMPAC’s comprehensive oncology information system is designed specifically to help chemotherapy centres by providing process automation tools that improve process efficiencies while reducing the risks of medical errors.
According to Dr Maurice Slevin, consultant oncologist and one of the founding partners of the London Oncology Clinic, IMPAC was selected because of their ability to understand the unique requirements of delivering cancer care and translate those needs into valuable software solutions. Dr Slevin stated, “The workflow of the system complements the oncologist and nurse, and their interaction with patients. All of the information currently stored in paper charts will be converted into an electronic format to enable immediate access by the entire staff, with appropriate security levels, whenever and wherever needed. The breadth and ease of access to this treatment information is unparalleled.”
From initial diagnosis and staging through planning, treatment, and subsequent follow up, the system will help staff accurately record and efficiently process critical data throughout the patient’s complete cycle of care. “We are very pleased to partner with a prestigious site such as the London Oncology Clinic,” said David Auerbach, president of IMPAC’s International Operations. “The integration of IMPAC’s chemotherapy electronic charting system will provide the London Oncology Clinic with leading-edge tools to improve patient care by managing the entire spectrum of critical patient data.”
Irena Goldman, chief executive of the London Oncology Clinic stated, “Our plans for future growth are well supported by IMPAC’s system with its built-in capability to accommodate both chemotherapy and radiotherapy patient treatment planning, all within a single application. A further critical factor in our decision making was that IMPAC allows for full integration with secure external data sources such as complex pathology testing, and radiology. This will provide our consultants with a complete and holistic view of their individual patients; a service central to the core values and motivation behind the inception of the London Oncology Clinic.”
IMPAC was founded in 1990 to develop an integrated clinical and administrative management system tailored specifically for cancer care and now has more than 2500 installations in 56 countries worldwide -- including over half of the top North American cancer centres. IMPAC’s chemotherapy electronic charting and order management solution will be on display at the annual European Society for Medical Oncology (ESMO) meeting in Vienna, Austria from 30 October through 2 November 2004.
About IMPAC Medical Systems
IMPAC Medical Systems, Inc. is a leading provider of oncology IT solutions that streamline both clinical and business operations to help improve the process of delivering quality patient care. With systems designed for anatomic pathology, medical oncology, radiation oncology, imaging, clinical laboratory, and cancer registry, IMPAC supports the entire team of healthcare professionals who contribute to the care of the cancer patient. Supporting more than 2500 installations worldwide, IMPAC provides practical solutions that deliver better overall communication, process efficiency and quality patient care. For more information about IMPAC products and services, please call +1-650-623-8800 or visit http://www.impac.com/.
The statements contained in this press release that are not purely historical are forward looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, including statements regarding the Company’s expectations, beliefs, hopes, intentions or strategies regarding the future. Forward looking statements include statements regarding the Company’s review of its revenue recognition policies and the estimated impact of the proposed financial restatement of previously report results, possible delisting from The NASDAQ Stock Market, business strategy, timing of, and plans for, the introduction of new products and enhancements, future sales, market growth and direction, competition, market share, revenue growth, operating margins and profitability. All forward looking statements included in this document are based upon information available to the Company as of the date hereof, and the Company assumes no obligation to update any such forward looking statement. Actual results could differ materially from the Company’s current expectations. Factors that could cause or contribute to such differences include the Company’s ability to expand outside the radiation oncology market or expand into international markets, our inability to recognize revenue from multiple element software contracts where certain elements have been delivered, installed and accepted but other elements remain undelivered, lost sales or lower sales prices due to competitive pressures, the ability to integrate its products successfully with related products and systems in the medical services industry, reliance on distributors and manufacturers of oncology equipment to market its products, changes in Medicare reimbursement policies, the integration and performance of acquired businesses, and other factors and risks discussed in the 10-K/A and other reports filed by the Company from time to time with the Securities and Exchange Commission.
CONTACT: Mark Arnoldk, International Marketing Manager of IMPAC Medical Systems, +44 (0)1784 410 416, or pr@impac.com.
IMPAC Medical Systems
CONTACT: Mark Arnoldk, International Marketing Manager of IMPAC MedicalSystems, +44 (0)1784 410 416, or pr@impac.com
Web site: http://www.impac.com/